Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse

Sunil Iyengar, Andrew Clear, Csaba Bödör, Lenushka Maharaj, Abigail Lee, Maria Calaminici, Janet Matthews, Sameena Iqbal, Rebecca Auer, John Gribben, Simon Joel

Blood (2013) 121 (12): 2274–2284.

https://doi.org/10.1182/blood-2012-10-460832

Published: 2013

Journal Articles

IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model.

Lenushka Maharaj, Rakesh Popat, John G Gribben, Simon Joel

Blood (2012) 120 (21): 2949.

https://doi.org/10.1182/blood.V120.21.2949.2949

Published: 2012

Journal Articles

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

Sunil Iyengar, MD, Andrew James Clear, BSc, Csaba Bödör, PhD, Lenushka Maharaj, Janet Matthews, Rebecca Auer, MD, Sameena Iqbal, John G Gribben, Simon Joel

Blood (2012) 120 (21): 1652.

https://doi.org/10.1182/blood.V120.21.1652.1652

Published: 2012

Journal Articles

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Sunil Iyengar, MD, Andrew J. Clear, BSc, Andrew Owen, Lenushka Maharaj, MSc, Janet Matthews, Maria Calaminici, MD, Rebecca Auer, MD, Essam Ghazaly, MD, Sameena Iqbal, John G. Gribben, MD, DSc, Simon Joel, BSc(Hons), PhD

Blood (2011) 118 (21): 1654.

https://doi.org/10.1182/blood.V118.21.1654.1654

Published: 2011

Journal Articles

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

Matthew J. Streetly, Lenushka Maharaj, Simon Joel, Steve A. Schey, John G. Gribben, Finbarr E. Cotter

Blood (2010) 115 (19): 3939–3948.

https://doi.org/10.1182/blood-2009-10-251660

Published: 2010

Journal Articles

GCS-100 Targets Apoptosis and Cell Cycle Regulation in Myeloma Cells.

Matthew Streetly, BMBS, MRCP, MRCPath, Lenushka Maharaj, Simon P Joel, Finbarr E Cotter, FRCP, FRCPath, PhD

Blood (2009) 114 (22): 4923.

https://doi.org/10.1182/blood.V114.22.4923.4923

Published: 2009

Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel

Blood (2008) 112 (11): 1625.

https://doi.org/10.1182/blood.V112.11.1625.1625

Published: 2008

Journal Articles

The Novel HDAC Inhibitor UCL67022 Is Highly Potent in Multiple Myeloma and Non-Hodgkin’s Lymphoma and Is Enhanced by Bortezomib.

Lenushka Maharaj, Rakesh Popat, Angela Chahwan, Andrew T. Lister, James D. Cavenagh, Brian Middleton, Alf Rioja, Charles Marson, Simon P. Joel

Blood (2006) 108 (11): 2604.

https://doi.org/10.1182/blood.V108.11.2604.2604

Published: 2006

Journal Articles

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Sandra J. Strauss, MD, Lenushka Maharaj, MSc, Jim Stec, Anthony Boral, MD, PhD, Elizabeth Trehu, MD, David Schenkein, MD, Simon P. Joel, PhD, T. Andrew Lister, MD

Blood (2004) 104 (11): 1386.

https://doi.org/10.1182/blood.V104.11.1386.1386

Published: 2004

Journal Articles

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

Lenushka Maharaj, MSc, Sandra J. Strauss, MD, Jim Stec, Thomas A. Lister, Simon P. Joel, PhD

Blood (2004) 104 (11): 3294.

https://doi.org/10.1182/blood.V104.11.3294.3294

Published: 2004

NARROW

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse

IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model.

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death

GCS-100 Targets Apoptosis and Cell Cycle Regulation in Myeloma Cells.

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

The Novel HDAC Inhibitor UCL67022 Is Highly Potent in Multiple Myeloma and Non-Hodgkin’s Lymphoma and Is Enhanced by Bortezomib.

Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).

Mantle Cell and Follicular Lymphoma Samples Demonstrate Differing Sensitivity to Bortezomib in a Primary Culture System.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only